CLEW trained its AI using data on nearly 100,000 patients in ICUs. The AI-based algorithms are machine-learning models trained to predict such problems hours in advance. The product, CLEW-ICU, integrates care delivered by local and remote teams. According to the vendor, this clearance is the FDA’s first for technology in this category.

The healthcare technology revolution: AI-assisted doctors CLEWICU is the industry’s first-ever cleared device for predicting the likelihood of patient deterioration up to 8 hours in advance based on hemodynamic instability, enabling earlier evaluation and subsequent care plans.

The artificial intelligence ICU solution monitors and categorizes patient risk levels, helping providers identify patients whose health conditions are likely to deteriorate

A new artificial intelligence (AI) based ICU solution for predicting the likelihood of patient deterioration up to eight hours in advance has become the industry’s first ever device to receive clearance from the US Food and Drug Administration (FDA).

Developed by CLEW, the system gathers data from electronic health records, vital sign monitors and connected ICU devices, and uses machine learning models to calculate each person’s risk of their heart and blood flow becoming unstable.

After receiving emergency approval at the height of the pandemic outbreak, CLEW gets the official stamp – with a platform to optimize the Intensive Care Units

The U.S. FDA granted 510(k) clearance for Clew Medical Ltd.’s artificial intelligence (AI)-based solution that can predict hemodynamic instability in ICU patients eight hours in advance of deterioration. The system continuously monitors and stratifies patients by risk level to enable optimization of ICU resources.

CLEW Medical’s ICU tool uses machine learning models to identify patients whose conditions are likely to deteriorate.

The FDA has OK’d AI software that can predict worsening condition in ICU patients up to eight hours before the falloff produces symptoms.

CLEW Medical’s ICU tool uses machine learning models to identify patients whose conditions are likely to deteriorate.

CLEWICU is a artificial intelligence (AI) based ICU solution that can “predict hemodynamic instability in adult patients.”

“We are proud to have received this landmark FDA clearance and deliver a first-of-its-kind product for the industry, giving healthcare providers the critical data that they need to prevent life-threatening situations,” said Gal Salomon, co-founder and CEO of CLEW Medical.